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ABSTRACT
Bleeding resulting from the application of low-molecular-weight
heparins (LMWHs) may be treated with protamine sulfate, but
this treatment lacks efficiency; its action against antifactor Xa
activity is limited to ∼60%. Moreover, protamine sulfate can
cause life-threatening hypersensitivity reactions. We developed
diblock heparin-binding copolymer (HBC), which can neutralize
the anticoagulant activity of parenteral anticoagulants. In the
present study, we explored the safety profile of HBC and its
potential to reverse enoxaparin, nadroparin, dalteparin, and
tinzaparin in human plasma and at in vivo conditions. HBC-
LMWH complexes were characterized using zeta potential,
isothermal titration calorimetry, and dynamic light scattering.
The rat cardiomyocytes and human endothelial cells were used
for the assessment of in vitro toxicity. Male Wistar rats were
observed for up to 4 days after HBC administration for clinical
evaluation, gross necropsy, and biochemistry and histopath-
ological analysis. Rats were treated with LMWHs alone or
followed by short-time intravenous infusion of HBC, and
bleeding time and antifactor Xa activity were measured.
HBC completely reversed antifactor Xa activity prolonged
in vitro by all LMWHs with an optimal weight ratio of 2.5:1. The
complexes of HBC-LMWHs were below 5 mm. We observed
no effects on the viability of cardiovascular cells treated with
HBC at concentrations up to 0.05 mg/ml. Single doses up to
20 mg/kg of HBC were well tolerated by rats. HBC completely
reversed the effects of LMWHs on bleeding time and anti-
factor Xa activity in vivo after 20 minutes and retained
∼80% and ∼60% of reversal activity after 1 and 2 hours,
respectively. Well-documented efficacy and safety of HBC
both in vitro and in vivo make this polymer a promising
candidate for LMWHs reversal.
SIGNIFICANCE STATEMENT
Over the last decade, there has been significant progress in
developing antidotes for the reversal of anticoagulants. Until
now, there has been no effective and safe treatment for patients
with severe bleeding under low-molecular-weight heparin ther-
apy. Based on our in vitro and in vivo studies, heparin-binding
copolymer seems to be a promising candidate for neutralizing all
clinically relevant low-molecular-weight heparins.
Introduction
Low-molecular-weight heparins (LMWHs) represent a group
of parenteral anticoagulants for prevention and treatment of
several thrombotic disorders, that is, unstable angina, myocar-
dial infarction, and deep vein or cancer-associated thrombosis.
The global parenteral anticoagulant market is dominated
by LMWHs and is still growing. LMWHs offer numerous
advantages over standard unfractionated heparin (UFH),
including more predictable pharmacodynamics and phar-
macokinetics, less restrictive monitoring, safer subcutane-
ous administration, and more favorable overall safety
profile with reduced risk of nonhemorrhagic side effects
(Kearon et al., 2012).
LMWHs are not a homogenous group of anticoagulants and
may differ in their anticoagulant profiles, pharmacokinetic
properties, and recommended dosing regimens (Kearon et al.,
2012). LMWHs are obtained fromUFHby differentmethods of
depolymerization. The principal mechanism of the anticoag-
ulant action of LMWHs is similar and involves antithrombin.
All LMWHs catalyze antithrombin-mediated inactivation of
coagulation factors. Because not all molecules of LMWHs
contain 18 saccharide units that are necessary for factor IIa
(thrombin) inhibition, LMWHs have antifactor Xa to anti-
factor IIa activity ratios between 1.6:1 and 8:1. Differences in
antifactor Xa/antifactor IIa activity ratio between LMWHs
depend on their average molecular weight and molecular size
distribution (Gray et al., 2008). It was also shown in a cohort
study of more than 12,500 patients that LMWHs differ in the
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frequency of bleeding episodes (van Rein et al., 2017). In the
most clinical trials involving the management of thrombotic
disorders with LMWHs, the incidence of major bleeding was
between 1.5% and 4.7% and depended mainly on the type and
duration of anticoagulation used and on the indication claimed
(Simonneau et al., 1997; Hull et al., 2000; Turpie et al., 2002;
Petersen et al., 2004; Mismetti et al., 2005; Crowther and
Warkentin, 2008).
Severe bleeding related to LMWHs may be treated with
intravenous administration of protamine sulfate. Protamine
sulfate fully neutralizes LMWHs’ antifactor IIa activity,
but its action against antifactor Xa activity is limited to
∼60% (Garcia et al., 2012). In the retrospective study,
LMWH-induced active bleeding was effectively stopped in
66% of patients who received protamine (van Veen et al.,
2011). Protamine sulfate can also cause life-threatening
hypersensitivity reactions, such as hypotension, pulmonary
hypertension, noncardiogenic pulmonary edema, cardiovas-
cular collapse, and pulmonary vasoconstriction. Additionally,
several risk factors for severe hypersensitivity reactions to
protamine have been described, including rapid administra-
tion, previous administration of protamine or protamine
insulin, fish allergy, left ventricular dysfunction, and previous
vasectomy (Sokolowska et al., 2016). Therefore, each admin-
istration of protamine should be carefully considered, and
better alternatives for LMWHs reversal are required.
Several new reversal agents for LMWHs (mainly enoxa-
parin and tinzaparin) are being developed. Ciraparantag is
a cationic, synthetic small molecule designed as an antidote
for direct oral anticoagulants, UFH, and enoxaparin (Laulicht
et al., 2013). Andexanet alfa, a recombinant derivative of
factor Xa, has been designed to reverse the anticoagulant
effects of direct and indirect factor Xa inhibitors (Lu et al.,
2013). However, andexanet alfa has received approval only for
uncontrolled and life-threatening bleeding in patients treated
with oral anticoagulants: apixaban and rivaroxaban (Heo,
2018). Another antidote currently in the preclinical phase of
development is Universal Heparin Reversal Agent (UHRA).
UHRA, a synthetic dendrimeric polymer, has been designed to
reverse the anticoagulant activity of all available heparins
(Shenoi et al., 2014; Kalathottukaren et al., 2017a) . In
a recently published in vitro comparative study, UHRA
directly bound both UFH and enoxaparin. Andexanet alfa
and ciraparantag bound the above heparins relatively weakly.
For andexanet alfa and UHRA, binding correlated positively
with the neutralization activity. The authors did not observe
the reversal activity of ciraparantag in assays typically used to
assess anticoagulant effects (Kalathottukaren et al., 2018).
None of the three above antidotes have been approved by the
Food and Drug Administration for the management of
LMWH-induced bleeding.
Therefore, to address the significant and still-unmet clinical
need, we developed a heparin-binding polymer (HBC) [poly(-
ethylene glycol) (PEG) 41–poly(3-(methacryloylamino)propyl
trimethylammonium chloride) (PMAPTAC) 53], a reversal
agent for parenteral anticoagulants. HBC is a diblock syn-
thetic polymer that directly binds anticoagulant molecules
and effectively neutralizes their effects in the living organism
(Kalaska et al., 2016, 2018, 2019). In thiswork,we further explore
the potential of HBC to safely reverse LMWHswidely used in the
clinical practice (i.e., enoxaparin, nadroparin, dalteparin, and
tinzaparin) at in vivo conditions and in human plasma.
Materials and Methods
In Vitro Neutralization Assay. Enoxaparin, nadroparin, dalte-
parin, and tinzaparin were purchased from Sanofi-Aventis (France),
Aspen Notre Dame de Bondueville (France), Pfizer Europe MA EEIG
(UK), and Sigma-Aldrich (Germany), respectively. The neutralization
of the above LMWHs was analyzed by measuring antifactor Xa
activity in a 96-well plate reader (Synergy HTX, BioTek) according
to themodified kitmanufacturer instructions (BioMedicaDiagnostics,
Canada), as described previously (Kalaska et al., 2016). In brief,
sodium citrate–anticoagulated pooled plasma was obtained from
healthy rats or human volunteers by centrifugation of whole blood
at 3500 g for 20 minutes at 4°C. Two hundred microliters of pooled
plasma were mixed with 10 ml of LMWHs (20 mg/ml of plasma for
enoxaparin and tinzaparin; 2 U/ml for nadroparin and dalteparin).
After 150 seconds of incubation (37°C), 10 ml of a solution containing
increasing concentrations of HBC (0.01–0.1 mg/ml of plasma) was
added. After another 150 seconds of incubation (37°C), antifactor Xa
activitywasmeasured at 405 nm. All the procedures involving healthy
human volunteers were approved by the Local Ethics Committee of
the Medical University of Bialystok (Permit No. R-I-002/193/2019).
Zeta Potential Measurements. Zeta potential of all HBC-
LMWH complexes in ratios based on the in vitro neutralization assay
wasmeasured using a Zetasizer Nano-ZS (Malvern Instruments, UK).
The samples were prepared in PBS (pH 7.4), filtered through
a Chromafil filter (0.45 mm), and measured at 25°C. The data were
analyzed using the Malvern software.
Isothermal Titration Calorimetry Measurements. All iso-
thermal titration calorimetry (ITC) measurements were made using
Malvern MICRO-CAL PEAQ-ITC. HBC was dissolved in PBS; its
concentration was 12 g/l (0.001078 mol/l). LMWHs’ commercial
solutions were also diluted in PBS to concentrations of about 125
U/ml or 1.25mg/ml. Themeasurement temperature was 25°C, and the
mixing speed was 750 rpm. The measuring chamber contained 270 ml
of LMWH solution to which 19 portions of HBC solution, 2 ml each,
were added.
The binding constant (Ka) between a molecule of HBC and a free
binding site of a respective LMWH was calculated using the formula:
Ka 5
½bound HBC
½free  binding  sites  of   LMWH½free HBC
Dynamic Light Scattering Measurements. The size of com-
plexes formed by HBCs and LMWHs in ratios based on the in vitro
neutralization was studied with the dynamic light scattering (DLS)
technique. LMWHs were dissolved in PBS and bovine serum. To that
mixture, the HBC solutions in PBS were added, and the formation of
complexes wasmonitored byDLS using a Zetasizer Nano-ZS (Malvern
Instruments).
Cell Lines Used and Cell Viability Assay. Primary human
umbilical vein endothelial cells (HUVECs) (American Type Culture
Collection–1730) and nontransformed embryonic rat heart–derived
cells [H9c2(2-1), American Type Culture Collection CRL-1446] were
used as healthy control cell lines for assessment of the cardiovascular
system toxicity of HBC. HUVECs were cultured in Medium 199
containing 20% fetal bovine serum with cell growth supplements at
37°C in the atmosphere containing 5% CO2 and at 95% humidity. All
experiments were performed withmycoplasma-free cells. The ATPlite
luminescence test (Perkin Elmer Life Sciences) was used to assess the
proliferation and viability of HUVECs in vitro. Cells were seeded in
96-well plates, and after overnight incubation, the cells were treated
with increasing concentrations of HBC for 72 hours. Cells treated with
formulation buffer were used as a control. H9c(2-1) cells were cultured
in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum at 37°C in the atmosphere containing 5% CO2 and at
90% humidity. The experiment was carried out for 24 hours after
adding HBC to cell media. To assess cell viability, crystal violet (CrV)
assay was used (Popiołek et al., 2019). Briefly, cells were seeded into
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24-well plates at the density of about 1.1  104 cells/cm2. After
incubation, the medium was removed, and the cells were washed and
fixed using 1ml of 4% v/v formaldehyde/PBS and treated for 2minutes
with a CrV solution. Then, unbound CrV was removed by rinsing with
water. After drying, the destaining solution was added to each well
and left for 30 minutes. Finally, absorbance of the obtained solution at
540 nm was measured, which was proportional to the number of
living cells.
Animals. Male Wistar rats were obtained from the Centre of
Experimental Medicine in the Medical University of Bialystok,
grouped into cages as appropriate, and allowed to have ad libitum
access to sterilized tap water and standard chow in specific pathogen-
free conditions. All the procedures involving animals were approved
by the Local Ethical Committee on Animal Testing (Permit Nos. for
the safety study: 38/2017 and 85/2019; Permit Nos. for the efficacy
study: 15/2013 and 60/2018) and conducted in accordance to the
Directive 2010/63/EU of the European Parliament and the Council on
the protection of animals, Animal Research: Reporting of In Vivo
Experiments guidelines, and national laws.
Safety Study in Rats. Thirty-five male Wistar rats were ran-
domly assigned to five groups. HBC was administered into the tail
vein of six rats at the initial dose of 5 mg/kg. The rats were observed
continuously for the first 30 minutes after HBC administration for
clinical signs of toxicity. Then they were kept under observation for up
to 4 days after HBC administration (intermittently for 4 hours and
then at 6, 24, 48, 72, and 96 hours after HBC administration). Body
weights were recorded before HBC administration and before the
gross necropsy on day 4. Following aminimum of 1 day without severe
clinical findings, HBCwas administered to a group of six rats at a dose
of 10mg/kg. These rats were observed for clinical signs of toxicity. This
procedure was repeated in six rats treated with HBC at a dose of
20mg/kg and 10 rats treated withHBC at a dose of 40mg/kg. PBSwas
also administered to seven animals as a control group. On the 4th day,
four rats treated with PBS and four rats treated with HBC at the dose
of 40 mg/kg were anesthetized by an intraperitoneal injection of pento-
barbital (45 mg/kg), blood was collected from the heart and centrifuged,
and serum was used for the measurement of alanine aminotransferase
and aspartate aminotransferase activities and total bilirubin, urea,
and creatinine concentrations. Immediately after the blood collection,
the whole liver, lungs, kidney, and thymus were removed for routine
histological analysis using hematoxylin and eosin staining.
Efficacy Study in Rats. In the first procedure, 56 male Wistar
rats were randomly assigned to seven groups, anesthetized by an
intraperitoneal injection of pentobarbital (45 mg/kg), and placed in
a supine position on a heated operating table. The body weights
ranged from 200 to 250 g just before anesthesia induction. Nadroparin
(800 U/kg), dalteparin (800 U/kg), or tinzaparin (8 mg/kg) was
administered into the right femoral vein 10 minutes before the
measurement of bleeding time. HBC (20 mg/kg) was intravenously
infused (5 minutes) after LMWH administration. Bleeding time was
measured as described previously (Kalaska et al., 2015). If bleeding
was still present at the end of the 480-second observation period,
a value of 480 seconds was ascribed for the sake of statistical analysis.
Twenty minutes after anticoagulant administration, antifactor Xa
activity was analyzed with ELISA technique using a microplate
reader (Synergy HTX, BioTek) according to the kit manufacturer
instructions (BioMedica Diagnostics). If antifactor Xa activity was
more than or equal to 1 U/mg, a value of 1 U/mg was ascribed for the
sake of statistical analysis.
In the second procedure, 43 male Wistar rats were randomly
divided into six groups and anesthetized in the same manner as
described in the first procedure. Rats were weighted just before
anesthesia induction and the body weights ranged from 190 to 220
g. Nadroparin andHBCwere also administered in the same doses and
manner as described in the first procedure. Bleeding timewasmeasured
10 minutes before blood collection. Antifactor Xa activity was analyzed
1 or 2 hours after anticoagulant administration. Bleeding time and
antifactor Xa activity were measured as described above.
Statistical Analysis. In the in vivo study, n refers to the number
of animals in each experimental group. For each test, the experimen-
tal unit was an individual animal. The data are shown as mean6 S.D.
or median with lower and upper limits and analyzed with GraphPad
Prism 6 software (GraphPad Prism 6 software) using the unpaired
Student’s t test or Mann-Whitney test. P values less than 0.05 were
considered significant.
Results
The Synthesis of HBC (PEG41-PMAPTAC53) by
Controlled Radical Polymerization. The synthesis of
HBC by reversible-addition fragmentation chain transfer
polymerization technique and selection strategy of the leading
compound was previously described (Kalaska et al., 2016).
Reversible-addition fragmentation chain transfer is one of the
controlled/living radical polymerization processes, allowing
synthesis of very well-defined polymers in terms of molecular
weight and molecular weight dispersity. Briefly, a diblock
copolymer with the degrees of polymerization of PEG and
PMAPTAC blocks equal to 41 and 53, respectively, was
synthesized (Fig. 1). The cationic PMAPTAC198 homopoly-
mer was used as a control to assess the toxicity-reducing
activity of the PEG block.
Cell Viability Reduction. HUVECs and cardiomyocytes
were treated with the diblock HBC and a cationic PMAP-
TAC198 homopolymer. HUVEC viability was not negatively
affected by HBC and PMAPTAC198 at concentrations up to
0.05 mg/ml. Both studied polymers significantly impaired
HUVEC viability at concentrations of 0.15 mg/ml (Fig. 2A).
The conjugation of PMAPTACwith PEG significantly reduced
the negative effect of the polycation PMAPTAC block on
cardiomyocyte viability (Fig. 2B). At 0.15 mg/ml, the maximum
concentration studied, the viability of the cardiomyocytes
treated with HBC was still about 100%, whereas the viability
of those treated with PMAPTAC198 decreased to about 50%.
Efficacy in the In Vitro Study. HBC concentration-
dependently and completely reversed antifactor Xa activity
in vitro of enoxaparin, nadroparin, dalteparin, and tinzaparin
in rat and human sodium citrate–anticoagulated plasma with
an optimal ratio of 0.05 mg of the polymer for 0.02 mg of both
enoxaparin and tinzaparin and 2 U of both dalteparin and
nadroparin (Fig. 3). We chose the concentration and dose of
HBC for further in vitro and in vivo studies based on the
estimated ratios: 2.5 mg of HBC per 1 mg of enoxaparin and
tinzaparin and 2.5 mg of HBC per 100 U of dalteparin and
nadroparin.
Zeta Potential of HBC-LMWH Complexes. Based on
the effective neutralization ratios found, we next investi-
gated the zeta potential of the HBC-LMWH complexes. In
all cases, the zeta potential of complexes had a value close to
zero (Table 1). The polycation completely neutralized the
negative charge of LMWH molecules. Such a result was to
be expected when the proportion of polymers in the mixture
corresponded to the total binding of LMWH by polycation.
DLS measurement showed a relatively large diameter of
complexes due to potential values close to zero and the lack
of electrostatic stabilization of the particles. In the case of
tinzaparin, the complexes were the smallest.
Calorimetric Measurements and Thermodynamic
Parameters of the Complexation Reaction. Thermody-
namic parameters of the interactions between all studied
LMWHs and HBC are given in Table 1, and the integral
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enthalpies of interaction are shown in Fig. 4. For enoxaparin
and nadroparin, the drop inflection points in the respective
curves are less clearly defined than for dalteparin and
tinzaparin (Fig. 4, A and B vs. Fig. 4, C and D), which may
be due to higher dispersity of the molecular weight of the
former LMWHs.
The Size of LMWH-HBC Complexes. The size of com-
plexes formed by LMWHs andHBCs in PBS and bovine serum
was studied using DLS technique. The particle size of com-
plexes in PBS and serum have diameters increasing in the
following order: tinzaparin (120 and 220 nm), dalteparin (0.5
and 1mm), enoxaparin (0.8 and 5mm), and nadroparin (in both
cases, two populations 0.4/.5 and 0.2/.5mm). The presence of
the polycation itself in the serum only slightly affected the size
of the objects present in the mixture, and this effect can be
considered negligible. The particle size of the complex formed
in the serumwas, in all cases, smaller than the diameter of the
capillary blood vessels. A relatively large dimension equal to
a fraction of the size of blood cells will promote the rapid
elimination of complexes from the blood system (Fig. 5).
Safety in Animals. There were no significant HBC-
related effects on the body weight gain in rats treated for up
to 4 days at the doses of 5, 10, and 20 mg/kg. A 5% reduction in
body weight occurred in the group treated with HBC at the
dose of 40 mg/kg. Administration of HBC at the dose of
20 mg/kg resulted in slightly decreased locomotive activity
and apathy at approximately 3 hours postdose in 50% of rats.
We observed transient mild nasal swelling and edema of the
limbs in five rats. All rats treated with HBC at the dose of
40 mg/kg had decreased locomotive activity and apathy (both
10–15 minutes following HBC administration); 40% of rats
had an increased thirst (14–20 minutes following HBC
administration); 50% of rats had an increased secretion of
porphyrins (2 to 3 hours following HBC administration). All
these findings were resolved within approximately 24 hours
postdose. Furthermore, mild nasal swelling and edema of the
limbs were observed in 40% of rats treated with HBC at the
dose of 40 mg/kg. These findings appeared immediately
postdose and were resolved within approximately 6 hours.
HBC at the dose of 40mg/kg resulted in kidney congestion and
color heterogeneity in 40% of rats. Gross necropsy findings in
30% of rats included the presence of urinary white sediment.
Severe gross necropsy findings occurred in one rat and included
lung congestion, kidney congestion, color heterogeneity, thymus
congestion, and liver abnormalities. All rats survived the
experiment (Table 2). We found higher serum concentrations
of urea and creatinine in two out of four rats treated with HBC
at the dose of 40 mg/kg (Table 3). The same two rats presented
significant histopathological changes of acute tubular necrosis
in kidney tissue, whereas two others presented mild tubular
toxicity, which should not impair renal function. There were
small areas of slight congestion and inflammatory cell in-
filtration in the lungs. HBC did not cause significant histopath-
ological changes in other studied tissues (Fig. 6).
Fig. 1. Chemical structure of HBC (PEG41-PMAPTAC53)
(Kalaska et al., 2016).
Fig. 2. Effect of HBC and PMAPTAC198 on HUVECs (A) and cardiomyocyte viability (B). Results are shown as mean 6 S.D.
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Efficacy in Animals. All currently in vivo–studied
LMWHs (tinzaparin, dalteparin, and nadroparin) prolonged
bleeding time and increased antifactor Xa activity at all
studied time points. HBC completely reversed the effects of
LMWHs on bleeding time and antifactor Xa activity to the
approximate control values in a 20-minute window (Fig. 7).
Our previous study demonstrated that HBC also reversed an
increased bleeding time and antifactor Xa activity by enox-
aparin in the same animal model (Kalaska et al., 2016). We
observed an almost-complete reversal of bleeding time, and
antifactor Xa activity increased by nadroparin 1 hour from the
administration, whereas more than 60% of reversal activity
was maintained after 2 hours (Fig. 8).
Discussion
We have previously shown the ability of HBC to neutralize
UFH, enoxaparin, and fondaparinux. The complete reversal of
enoxaparin demonstrated the potential advantage of HBC
over protamine sulfate (Kalaska et al., 2016). In this work, we
evaluate the safety profile of HBC and its reversal activity
against dalteparin, nadroparin, and tinzaparin.We found that
HBC bound all tested LMWHs forming the smallest com-
plexes with dalteparin and tinzaparin. The efficacy and safety
studies in rats showed that HBC could be a universal antidote
for all LMWHs. We also confirmed the neutralization of all
LMWHs by HBC in human plasma.
Our in vitro studies investigated the cardiomyocyte viability
after exposure toHBC and PMAPTAC198 as a control to check
the cytotoxicity reduction of the block copolymer compared
with homopolymer. Reversal of heparins by cationic prot-
amine sulfate can cause right ventricular failure and brady-
cardia (Ocal et al., 2005; Sokolowska et al., 2016) and may
induce left ventricular dysfunction because of its direct effect
on cardiomyocyte contractile processes (Hird et al., 1995).
Because of the negative mitochondrial membrane potential in
cardiomyocytes, cationic compounds may be taken up by
mitochondria and may, therefore, lead to cardiomyocyte
Fig. 3. Neutralization of enoxaparin (A), nadroparin (B), dalteparin (C), and tinzaparin (D) by HBC in sodium citrate–anticoagulated plasma with the
antifactor Xa assay. Results are shown as mean 6 S.D.
TABLE 1


















Enoxaparin-HBC 1.49 6 0.63 0.47 6 0.02 92.4 6 19.9 8.35 6 0.54 26.87 215.2
Nadroparin-HBC 23.93 6 0.29 0.49 6 0.01 10.8 6 2.14 8.01 6 0.22 28.14 216.2
Dalteparin-HBC 20.13 6 0.08 0.38 6 0.01 1.42 6 0.64 9.86 6 0.22 29.35 219.2
Tinzaparin-HBC 25.29 6 1.29 0.69 6 0.01 6.51 6 1.68 8.68 6 0.26 28.45 217.1
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damage (Hasinoff et al., 2003, 2016). Indeed, cationic PMAP-
TAC198 homopolymer decreased cardiomyocyte viability,
whereas HBC had no significant effect on cell viability,
confirming a well-known strategy of copolymerization or
functionalization with PEG to reduce polycation toxicity
(Pasut and Veronese, 2012). Though HBC and PMAPTAC198
did not affect human endothelial cells viability in vitro at
concentrations up to 0.05 mg/ml, endothelial cells seem to be
more sensitive than cardiomyocytes to the effects of both
polycationic compounds applied in the higher concentration.
The reduced viability may result from their interaction with
the anionic surface of endothelial cells, as was shown in the
case of protamine sulfate (Chang and Voelkel, 1989).
HBC sufficiently reversed antifactor Xa activity increased
in vitro by studied LMWHs in the concentration of 0.025 mg/ml.
In contrast, protamine sulfate was partially effective and
showed an anticoagulant effect at concentrations higher than
0.05 mg/ml (Shenoi et al., 2014). The efficacious concentra-
tions of HBC were three to six times lower than those
maximums studied in the cardiomyocyte viability experi-
ment. UHRAs demonstrated complete tinzaparin neutrali-
zation at similar ratios (Shenoi et al., 2014). Andexanet alfa
in the concentration of ∼3 mM also completely reversed
enoxaparin (Lu et al., 2013). However, the authors focused
on one LMWH (tinzaparin or enoxaparin) and have not
investigated the cardiotoxicity.
We applied DLS and ITC techniques to understand the
mechanism of interaction between HBC and LMWHs. The
enthalpy of binding was positive, indicating an endothermic
interaction. It was a bit unexpected for electrostatic interac-
tion. However, endothermic interactions between oppositely
charged polyelectrolytes have been reported (Ma et al., 2009).
On the other hand, entropy values were positive, indicating
that the neutralization process is entropy driven. The values
of n vary from 0.38 to 0.69, indicating that one chain of HBC
may bindmore than onemolecule of an LMWH (from 1.4 to 2.6
on the average). This is not surprising, taking into account
that one HBC chain bears on the average 53 cationic groups,
whereas the chains of the LMWHs bear from about 22 to 32
negative sulfate groups (assuming they all have the same
charge density equal to 2.7 sulfate groups per disaccharide
repeat unit, i.e., a charge of 25/kDa) (Kalathottukaren et al.,
2017a). It means that the number of HBC cationic groups per
chain is about 1.6–2.5 times greater than that of LMWHs
anionic groups, which is close to 1/n, that is, the number of
LMWH chains complexed by one HBC chain. Moreover, the
value of n for HBC-enoxaparin can be compared with the
respective value for dendrimeric UHRA, for which the n value
varies from 0.17 to 0.28 (Shenoi et al., 2014), and indicates
that one UHRA dendrimer may bind from 3.6 to 5.9 chains of
enoxaparin. It is about two times more than the number of
enoxaparin chains complexed by one HBC molecule. Consid-
ering that the molecular weight of UHRA is .23 kDa
(i.e., almost twice that of HBC), the ability to bind enoxaparin
of UHRA and HBC is comparable in terms of enoxaparin
chains bound per kiloDalton of a polycation. The binding
constants for HBC-LMWH complexes are of the order of
107–108, so the binding is rather strong also when compared
Fig. 4. Estimated heat of binding for the titration of HBC into enoxaparin (A), nadroparin (B), dalteparin (C), and tinzaparin (D).
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with UHRA-enoxaparin binding for which Ka was of the order
of 104–105 (Shenoi et al., 2014).
The development of a reversal agent for LMWHs is a mul-
tistep process involving an evaluation of its safety. The
nonclinical safety evaluation mainly includes a character-
ization of toxic effects, gross necropsy observations, dose
dependence, and relationship to exposure. According to
International Conference on Harmonisation guidelines, it
Fig. 5. The size profile of enoxaparin-HBC
(A), nadroparin-HBC (B), dalteparin-HBC
(C), and tinzaparin-HBC (D) complexes in
the aqueous solutions (PBS, pH 7.4) and
bovine serum, and PBS and HBC (E) in
bovine serum obtained by the dynamic
light scattering analysis.
TABLE 2
Selected clinical and gross necropsy observations during safety study in rats
The values indicate a total number of observations/number of animals concerned.
Dose (mg/kg) 0 5 10 20 40
Selected clinical findings
Decreased locomotive activity 0/7 0/6 0/6 3/6 10/10
Apathy 0/7 0/6 0/6 3/6 10/10
Increased thirst 0/7 0/6 0/6 0/6 4/10
Secretion of porphyrins 0/7 1/6 1/6 0/6 5/10
Mild allergic reactions 0/7 1/6 0/6 5/6 4/10
Mortality 0/7 0/6 0/6 0/6 0/10
Selected gross necropsy findings
Lung congestion 0/7 1/6 0/6 1/6 1/10
Kidney congestion 0/7 0/6 0/6 0/6 4/10
Kidney color heterogeneity 0/7 1/6 0/6 0/6 4/10
Thymus congestion 0/7 0/6 0/6 1/6 1/10
Duodenum congestion 0/7 0/6 0/6 1/6 0/10
Pancreas congestion 0/7 0/6 0/6 1/6 0/10
Liver abnormalities 0/7 0/6 0/6 1/6 1/10
Urine sediments 0/7 0/6 0/6 0/6 3/10
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should support first-in-human clinical trials . Nonclinical
toxicity studies of themost promising LMWH-reversal agents,
ciraparantag and andexanet alfa, have been conducted in
different animal models. Ciraparantag was evaluated to
perform the core safety pharmacology studies in rat and dog
models. Based on the lack of adverse systemic toxicity and
mortality, doses of ciraparantag up to 35 mg/kg in dogs and
40 mg/kg in rats were chosen as maximum tolerated doses.
Ciraparantag in the single dose of 40 mg/kg was well tolerated
in dogs. There were mild signs of hypersalivation and loss of
balance. In rats, ciraparantag in a single dose of 40 mg/kg
caused decreased activity and red-stained nares (Sullivan
et al., 2015). Similar treatment-emergent adverse events were
observed in healthy volunteers later (Ansell et al., 2016). The
authors have not investigated LMWH-reversal effects of
ciraparantag in humans. Andexanet alfa was tested in a single
and repeat-dose toxicity study. It was administered to rats or
monkeys alone and in combination with apixaban, rivarox-
aban, or enoxaparin. There were no systemic or tissue
pathologies in studied animals after single intravenous
injections of up to 60 mg/kg. In registration data available at
Food and Drug Administration, five mortalities of rats treated
with andexanet alfa twice daily for 14 days were observed. In
monkeys, they found neither significant safety concerns nor
unexpected outcomes. All observations were transient or
reversible and included transient hypoactivity, labored respi-
ration, vomiting, and anaphylactic reaction (Lu et al., 2017).
Similarly to other antidotes (Kalathottukaren et al., 2017b),
we tested the toxicity of HBC administered without heparin.
Besides mild and occasional clinical and gross necropsy
findings, single doses up to 20 mg/kg of HBC were well
tolerated. We observed changes in rats’ behavior and signs
of organ damage in the group of rats treated with a dose of
40mg/kg of HBC. In some of the rats, we performed additional
biochemistry and histopathological analysis, which revealed
a sign of acute tubular necrosis and increased biochemical
markers of kidney damage in two cases. Nephrotoxicity may
result from the binding of cationic HBC with an anionic
surface of renal epithelial cells, similarly to the postulated
chemical interactions between crystals and epithelial cell
surfaces in kidney stone formation (Lieske et al., 1997;Wesson
and Ward, 2006). Similarly to protamine, the efficacious dose
of HBC for LMWHs reversal is closely related to the dose of
studied LMWH and is based on the estimated optimal mass
ratios. In the previous study (Kalaska et al., 2016), we used
HBC at the dose of 6 mg/kg that corresponded to 3 mg/kg of
enoxaparin. If we assume 3 mg/kg as a therapeutic dose of
enoxaparin in rats, the multiple to the no-observed-adverse-
effect-level and adverse level for HBC would be ∼4 and ∼8,
respectively. LMWHs were administered in supratherapeutic
doses to induce clinically relevant major bleeding. Indeed,
anticoagulation by LMWHs increased bleeding time and
antifactor Xa activity. The strong anticoagulant effect was
observed in 100% of the animals. HBC administered in dose
corresponding to 2.5:1 mass ratio, but not exceeding safety
dose of 20 mg/kg, completely reversed the effects of LMWHs
on bleeding time and antifactor Xa activity to the approxi-
mate control values in a 20-minute window. A similar study
has been conducted to determine the reversal effect of
andexanet alfa on enoxaparin. However, administration of
andexanet alfa only partially reversed antifactor Xa activity
and decreased bleeding in ∼80% of the animals in a rat
TABLE 3
Biochemical parameters in rats treated with HBC at the dose of
40 mg/kg
Results are shown as a median with lower and upper limits.
Vehicle HBC
Alanine transaminase, U/l 34.5 (25.0–40.0) 26.0 (19.0–34.0)
Aspartate aminotransferase, U/l 86.5 (76.0–94.0) 105.0 (67.0–147.0)
Total bilirubin, mg/dl ,0.15 ,0.15
Urea, mg/dl 42.0 (39.0–44.0) 229.0 (38.0–448.0)
Creatinine, mg/dl 0.20 (0.20–0.30) 0.95 (0.20–3.40)
Fig. 6. Representative micrographs of tissue sections of liver (A and B),
lung (C and D), renal cortex (E and F), renal medulla (G and H), and
thymus (I and J) 4 days after intravenous administration of PBS (left
column; A, C, E, G, and I) and HBC at the dose of 40 mg/kg (right column;
B, D, F, H, and J) in rats. Original magnification, 100; hematoxylin and
eosin staining.
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tail–transection model (Hollenbach et al., 2012). We further
evaluated time-related changes of the reversal activity of
HBC against nadroparin as an example, since HBC effect was
comparable for all studied LMWHs. The almost-complete
neutralization of bleeding time and antifactor Xa activity
was observed for 1 hour after a 5-minute infusion of HBC,
whereas more than 60% of its reversal activity was main-
tained after 2 hours. Based on the literature data (Ibrahim
et al., 2017), the inhibition of factor Xa activity by LMWH
expires after ∼6 hours from intravenous administration into
rats. Thus, if a reversal of anticoagulation longer than 2 hours
is needed for surgical intervention or during uncontrolled
bleeding, HBC should probably be administered second time
or, similarly to andexanet alfa, should be kept infused till the
end of surgery or bleeding. Andexanet alfa due to the short
half-life (∼1 hour) had to be infused additionally to non-
bleeding healthy volunteers to reverse activity of enoxaparin
(Crowther et al., 2014, Siegal et al., 2015). In the ANNEXA-4
trial, andexanet alfa was administered as an intravenous
bolus followed by a 2-hour infusion to 352 patients who had
major acute bleeding after administration of rivaroxaban,
apixaban, or enoxaparin. Of the 15 patients treated with
enoxaparin who could be evaluated for anticoagulation effi-
cacy, 13 (87%) were adjudicated as having at least good
hemostatic efficacy 12 hours after andexanet alfa infusion
(Connolly et al., 2019). Thus, a 2-hour interval seems to be
a convenient therapeutic window for the reversing of LMWHs
in patients, especially those with a high risk of thrombosis,
in which restoring of anticoagulant protection is needed. In
the case of LMWHs reversal, more clinical trials are required
to assess the effects of andexanet alfa on this drug-related
bleeding (Sartori and Cosmi, 2018). Ciraparantag, another
candidate for LMWHs reversal, was evaluated in rats and
healthy volunteers. It stopped tail bleeding in rats treated
with enoxaparin, and the effect was stronger than that of
protamine sulfate (Laulicht et al., 2013). In healthy volun-
teers, ciraparantag entirely and rapidly reversed the clotting
time induced by enoxaparin but also caused adverse events in
more than half of patients (Ansell et al., 2016).
Based on the previous studies on enoxaparin, one could
assume that other LMWHswould also be neutralized byHBC.
However, it would be impossible to conclude that HBC is an
efficient and safe reversal agent for all main LMWHs without
clear direct experimental evidence, especially because other
Fig. 7. Neutralization of nadroparin,
dalteparin, and tinzaparin by HBC in
rats as measured by bleeding time (A)
and antifactor Xa activity (B). ***P, 0.001
vs. vehicle; ###P , 0.001 vs. appropriate
low-molecular-weight heparin, unpaired
Student’s t test. Results are shown as
mean 6 S.D. and analyzed with Graph-
Pad Prism software 6.
Fig. 8. Time course of reversal of nadroparin by HBC in rats as measured by bleeding time (A and B) and antifactor Xa activity (C and D) 1 or 2 hours
after nadroparin administration. ***P, 0.001 vs. vehicle; #P, 0.05; ###P, 0.001 vs. nadroparin, unpaired Student’s t test. Results are shown as mean
6 S.D. and analyzed with GraphPad Prism software 6.
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antidotes were less effective against heparins with shorter
chains. We also expanded the panel of safety studies in
rodents and the toxicity in cardiomyocytes and characterized
in more detail the mechanism of binding. We confirmed the
efficacy of HBC against LMWHs in human plasma and its
safety in HUVECs. It seems that the reversal activity of HBC
after a single injection could last longer than the effect of
andexanet alfa, which needs to be infused tomaintain activity.
Nevertheless, the second injection or prolonged infusion of
HBCmay be required in some clinical scenarios depending on
howmuch timehaspassed sinceLMWHs injection andhowmuch
time is needed for surgical intervention. Thus, the evaluation of
repeated-dose toxicity togetherwith the estimation of the optimal
route of HBC administration in nonhuman primates is required
before the administration of HBC to patients.
To sum up, we present here a new pharmacological tool for
binding all heparins. The studies with protamine, andexanet alfa,
and ciraparantag show that there is still space for amore efficient,
safer, and cost-effective reversal agent indicated for LMWHs,
and yet no such antidote has been currently registered. The
results of safety experiments point to a therapeutic potential
of HBC administered in doses up to 20 mg/kg. We estimated
the neutralization weight ratio of HBC to LMWH for 2.5:1 in
rats. Then, we confirmed it in human plasma. Importantly,
HBC stopped bleeding from tail of heparinized rats and
brought to control level typical coagulation parameters used
in the clinical practice. HBC retained ∼80% and ∼60% of
reversal activity after 1 and 2 hours, respectively. Based on
this study, we may expect similar effect of HBC in patients
treated with LMWHs.
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